On Thursday, Halozyme Therapeutics, Inc. (NASDAQ:HALO) submitted a non-binding proposal to Evotec SE (NASDAQ:EVO) to acquire ...

After Halozyme Therapeutics (HALO) confirmed it has submitted a non-binding proposal to the boards of Evotec (EVO) to acquire Evotec for EUR ...

The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...

Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...

RBC Capital analyst Charles Weston maintained a Buy rating on Evotec (0IRF – Research Report) today and set a price target of €11.60. The ...

Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR ...

In Europe, the Stoxx Europe 600 declined 0.8% in morning trading. Evotec climbed 19.4% and Nibe Industrier Series B added 4.1%. On the other hand, Swedish Orphan Biovitrum dropped 5.5%, and Interpump ...

(Reuters) - Europe's STOXX 600 opened lower on Friday, dragged by technology and healthcare stocks, keeping the index on ...

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...

Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...

Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.